Q-omics provides the consensus-scored TTLL12 profile across patient tissues and cancer cell-line models. TTLL12 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TTLL12 is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, TTLL12 protein abundance shows 22,838 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRP, and LSCC as cancer lineages where TTLL12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL12 survival associations across molecular data types. TTLL12 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL12 RNA expression–survival associations across cancer types. High TTLL12 expression shows unfavorable associations in MESO, ACC, LIHC, LUAD and SKCM, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TTLL12 RNA expression.
This table summarizes TTLL12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTLL12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL12 shows lower tumor expression in THCA and higher tumor expression in KIRP, LUSC, LUAD, LIHC and KIRC. The KIRP box plot shows higher TTLL12 RNA expression in tumor versus normal tissue (log2 FC = +1.142, t-test p < 0.001).
This table shows molecular features associated with TTLL12 in patient tissues and cancer cell lines. In patient samples, TTLL12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
